Steglatro: Uses, Dosage & Side Effects
An SGLT2 inhibitor used to lower blood sugar in adults with type 2 diabetes, working by blocking glucose reabsorption in the kidneys
Steglatro (ertugliflozin) is an oral prescription medicine belonging to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class. It is used to improve blood sugar control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic medications. Steglatro works through an insulin-independent mechanism by blocking glucose reabsorption in the kidneys, causing excess sugar to be excreted in the urine. It may also contribute to prevention of heart failure in patients with type 2 diabetes. Available as 5 mg and 15 mg film-coated tablets, Steglatro is taken once daily in the morning and should be used alongside a healthy diet and regular exercise.
Quick Facts: Steglatro
Key Takeaways
- Steglatro (ertugliflozin) is an SGLT2 inhibitor that lowers blood sugar by blocking glucose reabsorption in the kidneys, causing approximately 30–50 grams of excess glucose to be excreted in the urine per day — a mechanism that works independently of insulin.
- It is approved for adults (18+) with type 2 diabetes and can be used alone or combined with metformin, sulfonylureas, DPP-4 inhibitors, or insulin; it may also help prevent heart failure in type 2 diabetes patients.
- The starting dose is 5 mg once daily in the morning, with possible escalation to 15 mg; dose adjustments may be needed when used alongside insulin or insulin secretagogues to reduce the risk of hypoglycemia.
- Diabetic ketoacidosis (DKA) is a rare but serious risk — even with near-normal blood glucose — and patients should be educated on recognizing symptoms such as nausea, vomiting, abdominal pain, extreme thirst, and fruity breath odor.
- Common side effects include genital yeast infections, urinary tract infections, and increased urination; Steglatro should not be used in pregnancy, breastfeeding, type 1 diabetes, or severe renal impairment.
What Is Steglatro and What Is It Used For?
Steglatro contains the active substance ertugliflozin, which belongs to a group of medicines known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. This drug class represents one of the newer approaches to managing type 2 diabetes and works through a fundamentally different mechanism compared with traditional antidiabetic agents. Rather than increasing insulin secretion or improving insulin sensitivity, SGLT2 inhibitors act on the kidneys to reduce the amount of glucose that is reabsorbed back into the bloodstream after filtration.
Under normal physiological conditions, the kidneys filter approximately 180 grams of glucose per day from the blood. Nearly all of this glucose is reabsorbed back into the bloodstream by sodium-glucose co-transporter proteins located in the proximal tubules of the kidneys. SGLT2 is responsible for roughly 90% of this reabsorption. By selectively and reversibly inhibiting SGLT2, ertugliflozin lowers the renal threshold for glucose, meaning that glucose begins to appear in the urine at lower blood glucose concentrations than would otherwise occur. This results in the excretion of approximately 30 to 50 grams of glucose per day in the urine, producing a clinically meaningful reduction in blood sugar levels.
Because the mechanism of action is independent of insulin secretion and insulin sensitivity, Steglatro can complement other antidiabetic therapies that work through different pathways. It is approved for use as monotherapy (when diet and exercise alone are insufficient and metformin is not appropriate), or in combination with a wide range of other diabetes medications including metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, pioglitazone, and insulin. The choice of combination therapy is typically guided by individual patient factors such as baseline HbA1c, cardiovascular risk profile, renal function, and tolerability considerations.
In addition to its glucose-lowering effects, Steglatro may provide modest benefits on body weight and blood pressure. The caloric loss from urinary glucose excretion (approximately 120–200 calories per day) typically leads to a modest weight reduction of 1–3 kg. The mild osmotic diuresis caused by glucosuria and natriuresis can also produce a small reduction in systolic blood pressure (approximately 3–5 mmHg). These ancillary effects may be clinically beneficial for many patients with type 2 diabetes who also have overweight or hypertension.
Type 2 Diabetes Mellitus
Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency. The pancreas continues to produce insulin, but the body’s cells do not respond to it effectively, and over time the pancreatic beta cells may produce less insulin. This leads to persistently elevated blood glucose levels (hyperglycemia), which, if left uncontrolled, can cause serious long-term complications including cardiovascular disease, chronic kidney disease, diabetic retinopathy (eye damage), peripheral neuropathy (nerve damage), and impaired wound healing. Type 2 diabetes affects approximately 462 million people worldwide and is strongly associated with obesity, sedentary lifestyle, and genetic predisposition.
Unlike many other diabetes medications, Steglatro does not rely on insulin to lower blood sugar. By acting directly on the kidneys to reduce glucose reabsorption, it provides effective blood sugar control regardless of beta-cell function or the degree of insulin resistance. This makes it a valuable addition to treatment regimens where additional glucose lowering is needed without further burdening the insulin pathway.
What Should You Know Before Taking Steglatro?
Contraindications
There are specific situations in which Steglatro must not be used. The primary contraindication is hypersensitivity (allergy) to ertugliflozin or any of the excipients in the formulation. Signs of an allergic reaction may include skin rash, itching, swelling of the face, lips, tongue, or throat, and difficulty breathing. If you experience any of these symptoms, stop taking the medication and seek medical attention immediately.
Steglatro is not intended for use in patients with type 1 diabetes. The SGLT2 inhibitor mechanism can increase the risk of diabetic ketoacidosis (DKA) in type 1 diabetes patients, and the drug has not been studied or approved for this indication. If you have type 1 diabetes, your doctor will prescribe alternative treatments.
Warnings and Precautions
Rare cases of diabetic ketoacidosis have been reported with SGLT2 inhibitors, including Steglatro. DKA can occur even when blood sugar levels are not very high (euglycemic DKA). Seek immediate medical attention if you experience rapid weight loss, nausea or vomiting, abdominal pain, extreme thirst, rapid deep breathing, confusion, unusual sleepiness, a sweet or fruity breath odor, or a metallic taste in the mouth. The risk may increase during prolonged fasting, excessive alcohol consumption, dehydration, sudden reduction of insulin dose, or major surgery or serious illness.
Before and during treatment with Steglatro, discuss the following with your doctor:
- Kidney problems: Your doctor should check your kidney function before starting Steglatro and periodically during treatment. The drug’s glucose-lowering effect depends on adequate kidney function, and it is not recommended in patients with severely impaired renal function (eGFR below 30 mL/min/1.73 m²).
- Urinary tract infections: If you have a history of recurrent urinary tract infections, inform your doctor. The increased glucose concentration in the urine may promote bacterial growth and increase the risk of urinary tract infections.
- Genital yeast infections: SGLT2 inhibitors commonly cause genital mycotic infections (yeast infections) due to the glucose-rich urinary environment. Tell your doctor if you have a history of vaginal or penile yeast infections.
- Risk of dehydration: Steglatro causes mild osmotic diuresis, which increases urine output. Patients taking diuretics, those with low blood pressure, or those aged 65 and older may be at increased risk of dehydration. Ensure adequate fluid intake and report symptoms such as dizziness, lightheadedness, or fainting.
- Foot care: It is important to check your feet regularly and follow all foot care advice from your healthcare provider, as rare cases of lower limb amputation have been observed with SGLT2 inhibitors as a class (primarily with canagliflozin).
A rare but very serious and potentially life-threatening infection of the tissue between the genitals and anus has been reported with SGLT2 inhibitors. Seek immediate medical attention if you experience pain, tenderness, redness, or swelling of the genital area or area between the genitals and rectum, together with fever or feeling generally unwell. This condition requires urgent treatment.
Pregnancy and Breastfeeding
Steglatro should not be used during pregnancy. It is not known whether ertugliflozin can harm an unborn baby, and the effects on the developing fetus have not been adequately studied in humans. If you are pregnant, think you may be pregnant, or plan to become pregnant, speak with your doctor about the most appropriate way to control your blood sugar during pregnancy. Alternative diabetes treatments with a more established safety profile in pregnancy are available.
It is also not known whether ertugliflozin passes into breast milk. Because of the potential risk to the nursing infant, Steglatro should not be used during breastfeeding. Discuss alternative approaches to feeding your baby and managing your diabetes with your healthcare provider.
Driving and Operating Machinery
Steglatro itself has little or no effect on the ability to drive or use machines. However, when taken in combination with insulin or medications that stimulate insulin release from the pancreas (such as sulfonylureas), blood sugar may drop too low (hypoglycemia). Symptoms of hypoglycemia — including shakiness, sweating, visual changes, dizziness, and confusion — can impair your ability to drive safely. Do not drive or operate machinery if you feel dizzy or lightheaded while taking Steglatro.
Excipient Information
Steglatro tablets contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, speak with your doctor before taking this medicine. The tablets also contain sodium, but less than 1 mmol (23 mg) per tablet, meaning they are essentially sodium-free.
Urine Glucose Testing
Due to the way Steglatro works, your urine will test positive for glucose while you are taking this medicine. This is expected and not a cause for concern. However, inform any healthcare professional performing urine tests that you are taking an SGLT2 inhibitor, as this may affect certain laboratory results.
Children and Adolescents
Steglatro has not been studied in children and adolescents under 18 years of age. It is not known whether the medicine is safe and effective in this age group, and therefore it should not be used in pediatric patients.
How Does Steglatro Interact with Other Drugs?
Ertugliflozin is primarily metabolized by UGT1A9 and UGT2B7 (uridine diphosphate-glucuronosyltransferase enzymes), with minimal involvement of the cytochrome P450 (CYP) enzyme system. This means it has a relatively low potential for pharmacokinetic drug interactions compared with many other medications. However, pharmacodynamic interactions — where two drugs have additive or opposing effects on the body — are clinically relevant and should be considered when prescribing Steglatro.
Always tell your doctor or pharmacist about all medications you are taking, have recently taken, or might take, including prescription medications, over-the-counter drugs, herbal products, and dietary supplements. The following interactions are the most clinically important:
Major Interactions
| Drug / Class | Interaction | Clinical Action |
|---|---|---|
| Insulin | Combined glucose-lowering effect increases hypoglycemia risk | Lower the dose of insulin when initiating Steglatro; monitor blood glucose closely |
| Sulfonylureas (e.g., glimepiride, gliclazide) | Both drugs lower blood sugar; additive hypoglycemia risk | Consider reducing sulfonylurea dose; increased blood glucose monitoring |
| Loop & Thiazide Diuretics (e.g., furosemide, hydrochlorothiazide) | Additive diuretic effect; increased risk of dehydration and hypotension | Monitor hydration status, blood pressure, and electrolytes; ensure adequate fluid intake |
Minor Interactions
| Drug / Class | Interaction | Clinical Action |
|---|---|---|
| Metformin | No pharmacokinetic interaction; complementary glucose-lowering mechanisms | No dose adjustment needed; commonly used together |
| Sitagliptin (DPP-4 inhibitor) | No clinically meaningful pharmacokinetic interaction | No dose adjustment needed; can be combined (available as Steglujan fixed-dose combination) |
| ACE Inhibitors / ARBs | Additive blood pressure lowering; slight increase in dehydration risk | Monitor blood pressure; generally well-tolerated together |
| UGT Inducers (e.g., rifampicin, phenytoin) | May reduce ertugliflozin plasma levels through increased UGT metabolism | Monitor glycemic control; dose adjustment generally not required but consider closer monitoring |
Pharmacokinetic studies have shown that ertugliflozin does not significantly affect the plasma concentrations of commonly co-administered diabetes drugs such as metformin, sitagliptin, or glimepiride. Similarly, co-administration with metformin, sitagliptin, or glimepiride does not significantly alter ertugliflozin exposure. No dose adjustments are generally required when combining Steglatro with other antidiabetic agents, aside from potential insulin or sulfonylurea dose reductions to mitigate hypoglycemia risk.
What Is the Correct Dosage of Steglatro?
Always take Steglatro exactly as your doctor or pharmacist has told you. Do not change your dose unless instructed by your healthcare provider. The tablets should be swallowed whole; if you have difficulty swallowing, the tablet may be split or crushed. Take one tablet every morning, preferably at the same time each day, to help you remember. Steglatro can be taken with or without food.
Adults
Standard Adult Dosage
Starting dose: 5 mg once daily in the morning
Dose escalation: May be increased to 15 mg once daily if additional glycemic control is needed and 5 mg is well tolerated
Maximum dose: 15 mg once daily
| Patient Group | Starting Dose | Maximum Dose | Notes |
|---|---|---|---|
| Adults (18–64 years) | 5 mg once daily | 15 mg once daily | Take in the morning with or without food |
| Elderly (65+ years) | 5 mg once daily | 15 mg once daily | No dose adjustment based on age; monitor renal function and hydration |
| Mild renal impairment (eGFR 60–89) | 5 mg once daily | 15 mg once daily | No dose adjustment needed |
| Moderate renal impairment (eGFR 30–59) | Not recommended to initiate | N/A | Reduced efficacy; monitor and discontinue if eGFR persistently below 30 |
| Severe renal impairment (eGFR <30) | Contraindicated | N/A | Insufficient efficacy; do not use |
| Hepatic impairment | 5 mg once daily | 15 mg once daily | No dose adjustment for mild-to-moderate; limited data in severe impairment |
Children and Adolescents
Steglatro has not been approved for use in children and adolescents under 18 years of age. The safety and efficacy of ertugliflozin in pediatric patients have not been established, and the drug should not be prescribed for this age group.
Elderly Patients
No dose adjustment is required based on age alone. However, elderly patients are more likely to have reduced kidney function and a greater susceptibility to dehydration and volume depletion. Your doctor should assess your renal function before starting Steglatro and periodically during treatment. Adequate fluid intake should be ensured, and blood pressure should be monitored, particularly during the initial weeks of therapy.
Missed Dose
If you forget to take a dose of Steglatro, the course of action depends on how much time remains until your next scheduled dose:
- 12 hours or more until next dose: Take the missed dose as soon as you remember. Then take your next dose at the usual time.
- Less than 12 hours until next dose: Skip the missed dose entirely. Take your next dose at the regular scheduled time.
Never take a double dose (two doses on the same day) to make up for a forgotten dose. If you are unsure what to do, contact your doctor or pharmacist for guidance.
Overdose
If you take more Steglatro than prescribed, contact your doctor or pharmacist immediately, or go to your nearest hospital emergency department. While no specific antidote exists for ertugliflozin overdose, supportive measures should be initiated as clinically appropriate. Due to the drug’s high protein binding (approximately 93.6%), ertugliflozin is not expected to be significantly removed by hemodialysis. In an overdose situation, monitor blood glucose levels, hydration status, and electrolytes, and provide supportive care as needed.
Do not stop taking Steglatro without first consulting your doctor. Discontinuing the medication abruptly can cause your blood sugar levels to rise, potentially worsening your diabetic control. If you need to stop treatment for any reason — such as before surgery or during serious illness — your doctor will advise you on how to manage your blood sugar in the interim.
What Are the Side Effects of Steglatro?
Like all medicines, Steglatro can cause side effects, although not everybody gets them. Most side effects are related to the drug’s mechanism of action — by increasing glucose in the urine, SGLT2 inhibitors create an environment in the urinary tract and genital area that is more favorable for infections. Understanding the potential side effects and their frequency can help you recognize them early and seek appropriate medical advice.
Contact your doctor or go to the nearest hospital immediately if you experience signs of diabetic ketoacidosis (nausea, vomiting, abdominal pain, rapid deep breathing, confusion, unusual sleepiness, sweet breath odor) or signs of Fournier’s gangrene (pain, tenderness, redness, or swelling of the genitals or the area between the genitals and anus, with fever or feeling unwell).
Very Common
May affect more than 1 in 10 people
- Vaginal yeast infection (vulvovaginal candidiasis / thrush)
- Urinary tract infections
Common
May affect up to 1 in 10 people
- Yeast infection of the penis (balanitis or balanoposthitis)
- Changes in urination (increased frequency, urgency, larger volume, or nocturia)
- Thirst
- Vaginal itching
- Dehydration (dry mouth, dizziness, lightheadedness, weakness, fainting)
- Hypoglycemia (low blood sugar) — when used with insulin or sulfonylureas
- Changes in blood urea nitrogen levels
- Changes in LDL cholesterol levels
- Changes in hemoglobin levels (increased red blood cell count)
Uncommon
May affect up to 1 in 100 people
- Changes in serum creatinine (related to kidney function)
Rare
May affect up to 1 in 1,000 people
- Diabetic ketoacidosis (DKA) — can occur even with normal or near-normal blood glucose
Not Known
Frequency cannot be estimated from available data
- Necrotizing fasciitis of the perineum (Fournier’s gangrene)
- Skin rash
Understanding Common Side Effects
Genital yeast infections are among the most frequently reported side effects of all SGLT2 inhibitors, including Steglatro. The increased glucose concentration in the urine creates a favorable environment for Candida (yeast) organisms to grow. Women may experience vaginal itching, discharge, and discomfort (vulvovaginal candidiasis), while men may develop redness, itching, or swelling of the foreskin or head of the penis (balanitis). These infections are typically mild to moderate in severity and respond well to standard antifungal treatment. Maintaining good genital hygiene and keeping the area clean and dry can help reduce the risk.
Urinary tract infections (UTIs) are also common with SGLT2 inhibitor use. Symptoms include burning or pain during urination, cloudy urine, and pelvic or lower back pain (if the kidneys are involved). Most UTIs are uncomplicated and respond to standard antibiotic therapy. Seek immediate medical attention if you develop a fever or notice blood in your urine, as this may indicate a more serious infection requiring prompt treatment.
Increased urination is an expected pharmacological effect of Steglatro. Because the drug works by causing glucose to be excreted in the urine, you may notice that you urinate more frequently and produce larger volumes of urine, including during the night (nocturia). This typically becomes less noticeable over time as the body adjusts to the medication. Staying well hydrated is important, particularly in hot weather or during exercise.
Reporting Side Effects
If you experience any side effects — whether listed here or not — reporting them helps healthcare authorities monitor the ongoing safety profile of the medicine. You can report side effects through your national pharmacovigilance system, such as the FDA MedWatch program (in the United States), the Yellow Card Scheme (in the United Kingdom), or the EMA’s EudraVigilance system (in the European Union).
How Should You Store Steglatro?
Proper storage is essential to maintain the effectiveness and safety of your medication. Steglatro does not require any special storage conditions — simply store it at normal room temperature. There is no need for refrigeration.
- Keep out of sight and reach of children at all times to prevent accidental ingestion.
- Check the expiration date printed on the blister pack and outer carton (after “EXP”). The expiration date refers to the last day of that month. Do not use the medicine after this date.
- Do not use if the packaging appears damaged or shows signs of tampering.
- Proper disposal: Do not dispose of medicines in household waste or down the drain. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help protect the environment.
What Does Steglatro Contain?
Active Substance
The active substance in Steglatro is ertugliflozin, present in the form of ertugliflozin L-pyroglutamic acid. Each 5 mg film-coated tablet contains ertugliflozin L-pyroglutamic acid equivalent to 5 mg of ertugliflozin. Each 15 mg film-coated tablet contains ertugliflozin L-pyroglutamic acid equivalent to 15 mg of ertugliflozin.
Inactive Ingredients (Excipients)
Tablet core: Microcrystalline cellulose (E460), lactose monohydrate, sodium starch glycolate (type A), and magnesium stearate (E470b).
Film coating: Hypromellos 2910/6 (E464), lactose monohydrate, macrogol 3350 (E1521), triacetin (E1518), titanium dioxide (E171), and red iron oxide (E172).
Appearance and Pack Sizes
The 5 mg tablets are pink, triangular-shaped, approximately 6.4 × 6.6 mm, film-coated with “701” debossed on one side and plain on the other. The 15 mg tablets are red, triangular-shaped, approximately 9.0 × 9.4 mm, film-coated with “702” debossed on one side and plain on the other.
Steglatro is supplied in aluminium/PVC/PA/aluminium blisters. Pack sizes include 14, 28, 30, 84, 90, and 98 film-coated tablets in non-perforated blisters, and 30×1 film-coated tablets in perforated unit-dose blisters. Not all pack sizes may be marketed in every country.
Marketing Authorization Holder
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands. Steglatro is manufactured by Organon Heist bv (Belgium) and Merck Sharp & Dohme B.V. (The Netherlands).
Frequently Asked Questions About Steglatro
Steglatro (ertugliflozin) is used to lower blood sugar levels in adults aged 18 and older with type 2 diabetes mellitus. It can be used alone or together with other diabetes medications such as metformin, sulfonylureas, or insulin. It works by causing the kidneys to remove excess sugar through the urine. Steglatro may also help prevent heart failure in patients with type 2 diabetes. It is always used alongside a healthy diet and regular exercise program.
Steglatro works by blocking the SGLT2 protein in the kidneys. Normally, SGLT2 reabsorbs about 90% of the glucose that the kidneys filter from the blood. By inhibiting SGLT2, ertugliflozin prevents this reabsorption, causing approximately 30 to 50 grams of glucose to be excreted in the urine each day. This mechanism is independent of insulin, which makes it complementary to other diabetes treatments that work through the insulin pathway.
Yes, although rare, diabetic ketoacidosis (DKA) has been reported with SGLT2 inhibitors including Steglatro. A unique feature of SGLT2 inhibitor-associated DKA is that it can occur even when blood sugar levels are not markedly elevated (euglycemic DKA), which may delay recognition. Warning signs include rapid weight loss, nausea, vomiting, abdominal pain, extreme thirst, rapid deep breathing, confusion, unusual sleepiness, a sweet or fruity breath odor, or a metallic taste in the mouth. If you experience any of these symptoms, seek immediate medical attention. Risk factors include prolonged fasting, dehydration, excessive alcohol, reduced insulin doses, major surgery, or serious illness.
Steglatro (ertugliflozin), Jardiance (empagliflozin), Farxiga/Forxiga (dapagliflozin), and Invokana (canagliflozin) are all SGLT2 inhibitors that work by the same basic mechanism. They differ primarily in their dosing, pharmacokinetic profiles, and the clinical trial evidence supporting their use. Notably, empagliflozin and dapagliflozin have robust cardiovascular and renal outcome data showing benefits beyond glucose control (the EMPA-REG OUTCOME, DAPA-HF, and DAPA-CKD trials). In the VERTIS CV trial, ertugliflozin demonstrated non-inferiority for cardiovascular safety and a reduction in heart failure hospitalization, but did not show superiority for the primary composite endpoint of major adverse cardiovascular events. Your doctor will choose the most appropriate SGLT2 inhibitor based on your individual health profile.
Steglatro can lead to modest weight loss as a secondary effect. By causing 30–50 grams of glucose to be excreted in the urine daily, approximately 120–200 calories per day are lost. In clinical trials, patients taking Steglatro typically experienced weight reductions of about 1–3 kg (2–7 pounds) over 6 months. However, Steglatro is not approved as a weight-loss medication, and any weight change should be discussed with your doctor, particularly if the weight loss is rapid or unexplained, as this could be a sign of diabetic ketoacidosis.
No, Steglatro should not be used during pregnancy or breastfeeding. It is not known whether ertugliflozin can harm the unborn baby or pass into breast milk. If you are pregnant, planning to become pregnant, or breastfeeding, discuss alternative diabetes management options with your healthcare provider. Insulin is generally considered the preferred treatment for diabetes during pregnancy.
References
- European Medicines Agency (EMA). Steglatro – Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/steglatro
- U.S. Food and Drug Administration (FDA). Steglatro (ertugliflozin) Prescribing Information. Merck Sharp & Dohme Corp. Revised 2024.
- Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (VERTIS CV). N Engl J Med. 2020;383(15):1425–1435. doi:10.1056/NEJMoa2004967
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Suppl 1):S1–S352.
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycaemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023. Geneva: WHO; 2023.
- Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–540.
- Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab. 2019;21(4):1027–1036.
- British National Formulary (BNF). Ertugliflozin. NICE Evidence Services. Available at: bnf.nice.org.uk
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in endocrinology, diabetology, and clinical pharmacology.
Medical Content
iMedic Endocrinology Editorial Team – specialist physicians in diabetology and metabolic medicine with clinical experience in SGLT2 inhibitor therapies
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, ADA, and EASD guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.